Three simple solutions to prevent heart attacks and stroke worldwide have been proven effective by an international team led by Hamilton medical researchers.
The research team from the Population Health Research Institute (PHRI) of McMaster University and Hamilton Health Sciences studied more than 12,000 patients from 21 countries, including South Africa, to evaluate drugs that can prevent the cardiovascular diseases (CVD). These diseases lead to 18 million deaths and about 50 million heart attacks and strokes globally every year.
“These are incredibly important findings with potential for significant global impact,” said Dr. Salim Yusuf, principal investigator. “If just 10 percent of the world’s population at intermediate risk of CVD are impacted, we’re talking about 20 to 30 million people who could be helped by these drugs.”
The three methods examined included two established forms of therapy that of statins, a group of cholesterol-lowering drugs, and antihypertensives, a class of drugs used to treat high blood pressure. In addition, a combination of statins and antihypertensives was reviewed.
Three studies on the methods were published today in the New England Journal of Medicine. Under the name of HOPE-3, or Heart Outcomes Prevention Evaluation-3, the studies involved 228 centres looking at the effects of the three treatments in people at intermediate risk of, but without, clinical heart disease.
In South Africa the study was led by the National leader, Prof. Karen Sliwa, Director Hatter Institute of Cardiovascular Research, Faculty of Health Sciences, University of Cape Town, South Africa and Saheart president.
Statins proved to significantly and safely reduce CVD events by 25 per cent in patients at intermediate risk without CVD. Antihypertensives did not reduce major CVD events overall in the population studied, but did reduce such events in the group of people with hypertension, but not in those without hypertension. When combined, statins and antihypertensives reduced CVD events by 30 per cent—with a 40% benefit in those with hypertension, suggesting that patients with hypertension should not only lower their BP but also consider taking a statin.
The HOPE-3 research reports were led by Yusuf and Dr. Eva Lonn, both professors of medicine of McMaster’s Michael G. De Groote School of Medicine, and Jackie Bosch, an associate professor of the university’s School of Rehabilitation Science.
“The HOPE-3 trial brings clarity in the management of blood pressure and cholesterol, two of the most common cardiovascular risk factors,” said Lonn. “Primary prevention can be greatly simplified and made available to most intermediate-risk people worldwide.”
Bosch added: “Treatment with a statin was remarkably safe and beneficial in our study, regardless of cholesterol or blood pressure levels, age, gender or ethnicity. We are incredibly encouraged by the study’s results.”
‘”The Hope-3 trail is highly important for South Africa as there has recently been a substantial public debate about the long-term safety of statin treatment – this debate can now be put to rest as patients received treatment with statins over a period of up to 10 years’” said Prof. Karen Sliwa. “Stroke places a major burden of disease in South Africa- primary prevention using a statin could have a major impact as the agents have recently come of patent and are now more affordable.’’
HOPE-3’s findings will have a major influence on primary care in developed nations, where statins and antihypertensives are inexpensive, Yusuf added. While still relatively inexpensive in developing nations, the drugs are less affordable in relation to income. Still, Yusuf said the study’s results hold promise everywhere as the price of these drugs start to come down.
“These simple methods can be used practically everywhere in the world, and the drugs will become even cheaper as more and more systems and people adopt these therapies,” he said.
Yusuf, Lonn and Bosch are presenting the HOPE-3 trials at the 2016 American College of Cardiology (ACC) Scientific Session and Expo in Chicago this weekend.
The HOPE-3 study is funded by the Canadian Institutes of Health Research and AstraZeneca.
For more information, contact:
Faculty of Health Sciences
905-525-9140, ext. 22169
In South Africa: Prof. Karen Sliwa, MD, PhD, FESC, FACC
- Director: Hatter Institute of Cardiovascular Research in Africa, Faculty of Health Sciences, University of Cape Town, South Africa.
- Sa Heart President
Cell: +27 834574823